Bill Enright
William “Bill” Enright joined Vaxin in June 2008 and currently serves as President and CEO. Prior to joining Vaxin, Mr. Enright spent six years with GenVec, Inc. with increasing responsibilities including the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including approximately $140M of funding for vaccine related initiatives and moving four vaccines into clinical development. Mr. Enright brings 20 years of experience in a variety of positions within the life science/biotech industry. Mr. Enright was a self-employed consultant, where he provided business development and strategic marketing services to academic institutions, and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc. (now Invitrogen), working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.

Kent R. Van Kampen, D.V.M., Ph.D.
COO, has been CEO of several biotechnology companies including Virogenetics, a Division of Aventis Pasteur, the largest vaccine company in the world. While leading Virogenetics, the Division created multiple recombinant vaccines that are currently licensed in the veterinary market. Dr. Van Kampen brings a wealth of experience in the field of vaccinology, especially in research, development and commercialization. Earlier in his career, Dr. Van Kampen was the Department Head of Veterinary Sciences at Utah State University and Director of Physiological Research at Medtronic. He serves on the Boards of Vaxin Inc., HMV Corp., ImmunoMed Corp. and The Van Kampen Group Inc.

De-chu Tang, Ph.D.
Vice President and Chief Technical Officer, is Vaxin’s Scientific Founder. He obtained his PhD in Microbiology at Indiana University and did postdoctoral work at Baylor College of Medicine, Duke University, and the University of Texas Southwestern Medical Center before he joined faculty at the University of Alabama at Birmingham and subsequently founded Vaxin Inc. Dr. Tang was one of the first to have developed DNA vaccines and noninvasive epicutaneous vaccines. In October 2000, Dr. Tang received the prestigious Wallace H. Coulter Award for innovation and entrepreneurship.

Timothy J. Segers, J.D.
Corporate Counsel and Secretary, is a Partner with Balch & Bingham LLP. He is a member of the firm's Corporate, Tax and Finance section and Technology Law Counselors practice group. He is engaged primarily in a corporate and tax practice for clients ranging from emerging growth companies to publicly-traded companies. Mr. Segers corporate practice includes the areas of mergers and acquisitions, securities, business planning and general corporate matters. His tax practice is focused primarily on the federal and state taxation of corporations, partnerships and other pass-through entities.

Lyle A. Hohnke, Ph.D.
Chairman of the Board, Dr. Hohnke has served as general partner for Tullis-Dickerson since 1994. He has significant investment experience in early and expansion stage life science and technology oriented investments. He has served as the Chairman & CEO of Diamond Animal Health; general partner for Heart Land Seed Capital Fund in Des Moines, Iowa; Vice President for Research and Director of Patents and Licensing at the University of Connecticut Health Center; he founded and served as President of the University of Connecticut Research and Development Corporation where he co-founded several healthcare related University spin-off ventures including TargeTech, a gene therapy company. Dr. Hohnke’s professional career began at Pfizer Central Research where he served in successive positions and headed research and development of therapeutic agents for digestive diseases.
Dr. Hohnke currently serves on the board of several private biotechnology & healthcare companies, including TransMolecular Inc., Aldagen Inc. and Amistad Mission, a non-profit orphanage in Bolivia.

David J. Drutz, MD
Chairman Compensation Committee, serves as a member of the Board of Directors. His career spans 36 years in clinical medicine and patient care, basic and clinical research, pharmaceutical and biotechnology operational and research management and venture capital. Dr. Drutz is President of Pacific Biopharma Associates, LLC, a Chapel Hill, NC-based consulting company. In addition, he is Chairman of the Board of Tranzyme, Inc. located in Research Triangle Park, NC and Tranzyme Pharma Inc., Sherbrooke, Quebec, Canada. He also serves as a director of two public biotechnology companies: DARA BioSciences, Inc. (DARA:NASDAQ), Raleigh, NC, and MethylGene Inc. (TSX: MYG), Montreal, Quebec, Canada. Dr. Drutz's past experiences include Professor of Medicine and Microbiology and Chief Division of Infectious Diseases, University of Texas Health Science Center in San Antonio, Texas; Vice President, Biological Sciences and Vice President, Clinical Investigation for Smith Kline & French Laboratories; and Vice President Clinical Development, Daiichi Pharmaceutical Corporation. He has also served as President and Chief Executive Officer of two drug discovery and drug development companies, Sennes Drug Innovations Inc., Houston, Texas; and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH), Durham, North Carolina. Dr. Drutz holds a current Certificate of Director Education from the National Association of Corporate Directors (NACD).

Michael Rice
Chairman Audit Committee, is an experienced healthcare investment banker and capital markets professional with expertise in the life sciences sectors: biopharmaceutical, medical technology, specialty pharmaceutical, and diagnostics companies. He has strong execution capabilities across a broad range of products including equity and equity-linked offerings, private placements, and fixed income transactions. He has served as the Managing Director - Life Sciences Investment Banking, Cannacord Adams, New York, NY; Managing Director Head of Healthcare Equity Capital Markets, Thinkequity Partners/ Thinkpanmure, New York, NY; Managing Director –Private Client Services, Bank of America, New York, NY; Managing Director, JP Morgan-Bear Stearns-Alex Brown & Song, New York, NY.

Ike Wan Lee, Ph.D.
Member of the Board, is currently the President/CEO, AnC Bio Holdings, Seoul, Korea. He has also served as the Co-Founder and Managing Partner, Alopax Consulting, Seoul, Korea; CEO, CHA Biotech, Seoul, Korea (currently CHA Biotecgh & Diostech); Co-Founder, Chief Scientific Officer, Cardio3 SA, Braine-l’Alleud, Belgium (currently Cardio3 Biosciences); Director of Technology, Ivrea Laboratories, Inc., and Cellentech, Quincy, Massachusetts; Co-Founder, Chief Scientific Officer and Executive Vice President, Anterogen Co., Ltd., Boston, Massachusetts and Seoul, Korea; Research Associate and Instructor, Cardiovascular Division, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts; and Senior Scientist, AlphaGene, Inc., Charlestown, Massachusetts.

Herbert (Herb) L. Heyneker, Ph.D.,
Member of the Board, serves as an advisor for Abingworth Bioventures and Utrecht-based Thuja Capital scouting for new investment opportunities and performing technical due-diligence. Herb is a serial entrepreneur founding multiple successful biotech companies. He has held positions with Eos Biotechnology, Inc., ProtoGene Laboratories, Inc., GlycoGen Inc., Genencor International Inc. and was the first scientist hired at Genentech. At Eos, he designed a highly parallel DNA synthesis instrument, which was used by a wholly-owned subsidiary of Eos to sell oligos over the web. This business was later acquired by Life technologies. He has also served on the board of directors for GenPharm and Guava Technologies in the US and in the Netherlands, IntroGene (acquired by Crucell), Pharming, Pepscan and Prosensa. He is currently a board member of Profibrix and Boreal Genomics.Herb consults as a scientific advisor for a range of biotechnology companies both in the US and the Netherlands. He is an author on more than 50 peer-reviewed papers and an inventor on more than 30 US patents.

Philip L. Hodges
Member of the Board, is a co-founder and Managing Director of Redmont Venture Partners, located in Birmingham, Alabama. Since 1997, Redmont has invested capital into early stage companies primarily in the healthcare and information technology sectors. His previous experience includes management positions at Atherotech, Tubular Products Corporation and HealthSouth. Mr. Hodges currently serves as a Director for the following companies: Allvivo, Entegreat, and Reliant Medical Products.

Bill Enright
President and CEO - See Management Team above.

John Petricciani, M.D.
is Senior Vice President, Medical and Regulatory Affairs at CancerVax Corporation. From 1992-1997, Dr. Petricciani served as VP, Regulatory Affairs at Genetics Institute, Inc. Prior to that, Dr. Petricciani held senior positions in the public an private sectors, including the FDA from 1973-1985, where he served as Director of the Office of Biologics, and the NIH from 1968-1972.

Gerald Quinnan, M.D., Ph.D.
had a 20-year career with the Biological Section of the FDA culminating in his being the acting Head of CBER for 3 years. He is now Department Head of Infectious Diseases at the Uniformed Medical Colleges in Bethesda, Md.

Richard Whitley, M.D.
is a distinguished Professor of Pediatrics, Microbiology, Medicine and Neurosurgery at the University of Alabama at Birmingham (UAB). Dr. Whitley also serves as vice-chair of the Department of Pediatrics, is the co-Director of the Center for Biodefense and Emerging Infections at UAB and currently is President of the Infectious Disease Society of America (IDSA). Dr. Whitley is one of the leading figures in the field of virology and infectious disease, and is internationally recognized for his contributions in antiviral research and the engineering of herpes simplex virus for gene therapy. He has served as author and co-author of more than 525 scientific writings in books and peer-reviewed scientific and medical journals. He is editor of Antiviral Research, and associate editor of the Journal of Infectious Diseases and Therapy. Dr. Whitley serves on numerous government and industry advisory committees, including VERBAC (FDA Vaccine Advisory Committee), the Board of Scientific Councilors for NIAID and on the working group for the Presidential Council of Advisors on Science and Technology (PCAST).